Philips, Masimo receive FDA clearance for patient monitor
By HME News Staff
Updated 10:02 AM CDT, Thu June 1, 2023
AMSTERDAM, and IRVINE, Calif. – Royal Philips and Masimo have received clearance from the U.S. Food & Drug Administration allowing the activation of SedLine Brain Function Monitoring, Regional Oximetry (O3), and CO₂ measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment. “Our work with Masimo has enabled us to forge new paths in continuous monitoring,” said Christoph Pedain, general manager, Hospital Patient Monitoring at Philips. “We’re connecting data and technologies to help arm care providers with the robust information they need to make timely, informed care decisions for their patients.” The integration can help clinicians assess and monitor blood saturation in the brain (cerebral oxygenation), anesthetic sedation, and patient respiratory performance with ease, all from the same monitor. The data can also be shared between monitors. These capabilities and metrics help care providers to act decisively while also helping to lower cost of care by providing a more holistic view of the patient from one system. Earlier this year, Masimo and Royal Philips announced an expansion of their partnership to augment remote patient monitoring capabilities in home telehealth applications with the Masimo W1 advanced health tracking watch.
Comments